Currently, the demand of GMP-grade psilocybin from research groups is fulfilled by chemical synthesis and mushroom extraction companies. However, the respective methods use expensive precursors or have low yields, ramping up the price of psilocybin. In contrast to chemical synthesis and mushroom extraction methods, we plan on engineering yeast strains to produce psilocybin cheaply - requiring only sugar (glucose) and water. 
With our knowledge of metabolic and network engineering, we will optimise this psilocybin biosynthesis pathway and direct cellular resources towards producing our product, thus decreasing price and increasing our yields. We will explore and compare the psilocybin synthesis pathways of different genuses of mushrooms which produce psilocybin and combine them to make the optimal pathway which is most efficient.
Additionally, our core technology is working on optimising performance characteristics of the psilocybin biosynthesis pathway to reach the purification levels required for our customers. Following this, we will be scaling-up production to industrial levels through methods that already exist in the brewing and the biopharmaceutical industry.